)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Biohaven
Biohaven (BHVN) investor relations material
Biohaven Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary10 Aug, 2026
Executive summary
Achieved significant clinical milestones, including advancing BHV-1300 into Phase 3 for Graves' disease, presenting compelling data for Graves' disease and IgA nephropathy, and reporting durable seizure control for opakalim in epilepsy.
Completed enrollment in pivotal epilepsy and obesity trials, with topline results expected in H2 2026.
Expanded oncology pipeline with new data for BHV-1530 and advanced collaborations for ADC programs.
No revenue generated from product sales; operations funded by equity and debt financings.
Strategic reprioritization in Q4 2025 to optimize costs and value generation.
Financial highlights
Net loss for Q2 2026 was $137.3M ($0.91/share), improved from $198.1M ($1.94/share) in Q2 2025.
R&D expenses for Q2 2026 were $100.8M, down from $184.4M in Q2 2025, reflecting strategic reprioritization and lower milestone payments.
G&A expenses for Q2 2026 were $24.1M, down from $27.3M year-over-year.
Cash, cash equivalents, and marketable securities at June 30, 2026 totaled $270.5M.
Non-GAAP adjusted net loss for Q2 2026 was $118.1M ($0.78/share), compared to $166.4M ($1.63/share) in Q2 2025.
Outlook and guidance
Pivotal Phase 3 readouts for BHV-1300 in Graves' disease and opakalim in epilepsy expected in H2 2026.
Pivotal study for BHV-1400 in IgA nephropathy to initiate in H2 2026.
Cash, cash equivalents, and marketable securities expected to fund operations for at least one year from the report date.
Continued advancement of pipeline candidates in neurology, immunology, and oncology.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biohaven
- Net loss narrowed to $130.5 million as cash reserves exceeded $350 million, supporting clinical progress.BHVN
Q1 2026 - Votes will be held on director elections, auditor ratification, and executive compensation.BHVNProxy Filing
- Director elections, auditor ratification, and Say-on-Pay headline a year of strategic execution.BHVNProxy Filing
- First-in-class degraders, novel CNS and obesity therapies, and oncology assets advance toward pivotal trials in 2026.BHVN44th Annual J.P. Morgan Healthcare Conference presentation
- Net loss narrowed as cost optimization and capital raises support pivotal trials in 2026.BHVNQ4 2025
- Proxy covers director elections, auditor ratification, executive pay, and governance highlights.BHVNProxy Filing
- Definitive additional proxy materials update shareholders on voting and securities matters.BHVNProxy Filing
- Q3 2025 saw a $173.4M net loss, major R&D cuts, and $263.8M in cash for near-term operations.BHVNQ3 2025
- Troriluzole slowed SCA progression by up to 70% over 3 years, with robust safety and efficacy.BHVNStudy Result
Next Biohaven earnings date
Q3 202612 Nov, 2026
Biohaven
Next Biohaven earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. The company's product candidates are either in various stages of clinical trials or pre-clinical trials.